- Home
- PEO vs AUTL Comparison
PEO vs AUTL Comparison
Compare PEO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEO
- AUTL
- Stock Information
- Founded
- PEO 1929
- AUTL 2014
- Country
- PEO United States
- AUTL United Kingdom
- Employees
- PEO N/A
- AUTL N/A
- Industry
- PEO Finance/Investors Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEO Finance
- AUTL Health Care
- Exchange
- PEO Nasdaq
- AUTL Nasdaq
- Market Cap
- PEO 596.4M
- AUTL 360.6M
- IPO Year
- PEO N/A
- AUTL 2018
- Fundamental
- Price
- PEO $20.02
- AUTL $1.35
- Analyst Decision
- PEO
- AUTL Strong Buy
- Analyst Count
- PEO 0
- AUTL 5
- Target Price
- PEO N/A
- AUTL $9.32
- AVG Volume (30 Days)
- PEO 35.4K
- AUTL 2.3M
- Earning Date
- PEO 01-01-0001
- AUTL 05-08-2025
- Dividend Yield
- PEO 5.93%
- AUTL N/A
- EPS Growth
- PEO N/A
- AUTL N/A
- EPS
- PEO N/A
- AUTL N/A
- Revenue
- PEO N/A
- AUTL $10,120,000.00
- Revenue This Year
- PEO N/A
- AUTL $277.74
- Revenue Next Year
- PEO N/A
- AUTL $221.89
- P/E Ratio
- PEO N/A
- AUTL N/A
- Revenue Growth
- PEO N/A
- AUTL 496.00
- 52 Week Low
- PEO $19.22
- AUTL $1.11
- 52 Week High
- PEO $23.80
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- PEO 44.68
- AUTL 46.99
- Support Level
- PEO $19.72
- AUTL $1.15
- Resistance Level
- PEO $20.05
- AUTL $1.44
- Average True Range (ATR)
- PEO 0.45
- AUTL 0.14
- MACD
- PEO 0.05
- AUTL 0.00
- Stochastic Oscillator
- PEO 40.56
- AUTL 35.09
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a closed-end equity investment company specializing in energy and other natural resources stocks. The investment objectives of the fund are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. Its portfolio of investments comprises of different sector investments such as in the energy sector and basic materials.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.